Luiz Magno
doctorMale0.0Global Dominance: 0.00%
Luiz Magno is a senior medical director at Eli Lilly Brazil, where he has been instrumental in the development and promotion of innovative treatments for diabetes and obesity, including the recent studies highlighting the effectiveness of tirzepatida (Mounjaro) over semaglutida (Wegovy) in weight loss.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Luiz Magno is the senior medical director of Eli Lilly in Brazil.
Qual o melhor remédio para perder peso? Estudo aponta que Mounjaro é 47% mais eficaz que o Wegovy e OzempicO Globo·
Brazil· 2025-03-20
Brazil· 2025-03-20Also mentioned
Leonard C Glass
Luiz Magno is the senior medical director at Eli Lilly do Brasil and explains the role of GIP in weight loss results.
Mounjaro supera Wegovy em perda de peso de paciente com obesidade, diz farmacêuticaO Estado de S. Paulo (Estadão)·
Liechtenstein· 2025-03-18
Liechtenstein· 2025-03-18Also mentioned
Bruno Geloneze